Perseus Proteomics, Inc. (4882) Press Release
Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I Clinical Trial of PPMX-T003 for Polycythemia Vera
Earlier from Perseus Proteomics
- (Amendments) Amendments to “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026”
- Perseus Proteomics: Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2023
- Perseus Proteomics: Notice on Determination of Stock Option (Share acquisition rights) Details
- Perseus Proteomics: Notice on Issuance of Stock Option (Share acquisition rights)